Mikhail Fedyanin MD

Blokhin's Russian Cancer Research Center · FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Mikhail Fedyanin MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:35 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT06978400 · A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center · recruiting · Neoplasms · principal investigator
Ph2
NCT06967155 · A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center · active not recruiting · Neoplasms · principal investigator
N/A
NCT04905329 · A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
Moscow Clinical Scientific Center · unknown · Solid Tumor, High-Risk Cancer, Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name.